REG-Arix Bioscience plc: Announces Board Changes

Arix BioscienceAnnouncement

12/09/2018 16:35

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU
MARKET ABUSE REGULATION NO.596/2014

Announces Board Changes

Appointment of Arthur Pappas to the Board of Directors

David U’Prichard to retire from Board

LONDON, 12 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global
healthcare and life science company supporting medical innovation, today
announced that industry veteran Arthur Pappas has been appointed as
Non-Executive Director to the Arix Board of Directors. Arix also announces,
David U’Prichard is retiring from the Board, effective immediately.

Jonathan Peacock, Executive Chairman of Arix, commented: “I am very pleased
to welcome Art to the Board of Arix. He brings extensive experience both as a
senior executive in the pharmaceutical industry and in building Pappas Capital
as a leading life sciences venture capital firm in the United States.

“On behalf of the Arix Board, I would like to thank David for his
contributions since joining Arix at its inception. We are grateful for the
commitment and support he has shown to the Company over the last three
years.”

Arthur Pappas commented: “Arix is committed to building and supporting the
development of young companies developing innovative therapies for important
unmet medical needs. Since IPO, Arix has grown significantly having built a
diverse and innovative portfolio, a unique group of industry and academic
partners, and a talented investment team in the UK and US. Arix offers a
compelling proposition to investors looking to access innovation in life
sciences, and I look forward to supporting the Company’s continued growth
and development.”

Arthur Pappas brings over 30 years of experience as a pharmaceutical and
biotechnology industry executive, and venture capital investor in life science
companies. He is the founder and managing partner of Pappas Capital, a leading
US venture firm. Prior to founding Pappas Capital in 1994, Art held senior
level leadership positions at several multinational pharmaceutical companies
for which he was responsible for the development, licensing and launch of a
number of global products. He was an executive member of the board of
directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s
chief executive responsible for international operations including research,
development and manufacturing. Prior to Glaxo, Art was Vice President of
Commercial Operations for Abbott International, and he held various executive
and general management positions with Merrell Dow Pharmaceuticals and the Dow
Chemical Company, in the United States and internationally. He previously
served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD)
(acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals
(acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational
Corp. (now part of IQVIA) (NYSE: IQV), TYRX (acquired by Medtronic in 2013),
Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics
(acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired
by Pfizer in 2006). He also served as a board observer for Plexxikon, which
was sold to Daiichi Sankyo in 2011.

Art is a member of the Board of Directors of the North Carolina Biotechnology
Center, where he was a past chair, and the Medical University of South
Carolina Foundation for Research Development. He is a member of the Board of
Trustees of The Wistar Institute (a National Cancer Institute center), the
Board of Advisors of the Duke Cancer Institute, and the Advisory Board of the
BioExec Institute. He is also a member of the CEO Roundtable on Cancer and
BayHelix, an organization of global life science community leaders. He
previously served on the Board of Directors of the National Venture Capital
Association. Art is a decorated Vietnam veteran, having served as an officer
in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK
Special Warfare Center.

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com  

Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 714 1787
optimum.arix@optimumcomms.com

Burns McClellan (US Media & IR Enquiries)
Lisa Burns, Nancie Steinberg
+1 212-213-0006
arix@burnsmc.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting
medical innovation. Headquartered in London and with an office in New York,
Arix Bioscience sources, finances and builds world class healthcare and life
science businesses addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough academic science
and strategic relationships with leading research accelerators and global
pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com



Copyright (c) 2018 PR Newswire Association,LLC. All Rights Reserved